skip banner navigation
National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Hepatocellular Cancer (PDQ®): Screening
Patient VersionHealth Professional VersionLast Modified: 03/23/2004




Summary of Evidence






Significance






Evidence of Benefit






Changes To This Summary (03/23/2004)






Questions or Comments About This Summary






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Dictionary

Funding Opportunities

NCI Publications

NCI Calendar

Español
NCI Highlights
October is Breast Cancer Awareness Month

NCI Annual Progress Report on Cancer Research 2003

Women, Tobacco and Cancer: Agenda for 21st Century

Past Highlights
Need Help?
Summary of Evidence

Note: Separate PDQ summaries on Adult Primary Liver Cancer Treatment and Childhood Liver Cancer Treatment are also available.

There is insufficient evidence to establish that screening by alpha-fetoprotein and/or imaging techniques (such as CT or ultrasound) would result in a decrease in mortality from hepatocellular cancer (HCC).

Level of Evidence

5: Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.

Back to TopBack to Top

Next Section >

skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health FirstGov.gov